Trelegy Shortage: What Providers and Prescribers Need to Know in 2026

Provider Briefing: Trelegy Ellipta Availability in 2026

If your patients are reporting difficulty filling Trelegy Ellipta prescriptions, the issue is real — even though the drug is not on the FDA's official shortage list. Intermittent stockouts at the pharmacy level, compounded by prior authorization delays and cost barriers, are creating a growing access problem for patients who depend on triple therapy for COPD and asthma maintenance.

This briefing covers what you need to know as a prescriber: current availability, the factors driving access issues, clinical alternatives, and tools you can use to help your patients stay on therapy.

Timeline: How We Got Here

Trelegy Ellipta was first approved by the FDA in September 2017 for COPD maintenance, and gained an expanded indication for asthma in adults in October 2020. Since then, prescriptions have grown steadily as evidence supports the benefits of single-inhaler triple therapy (SITT) over dual combinations for reducing exacerbations in moderate-to-severe COPD and uncontrolled asthma.

Key milestones affecting current availability:

• 2017–2020: Steady adoption in COPD; limited competition in the triple-inhaler space
• 2020: Asthma indication approval expanded the patient population significantly
• 2021–2024: Breztri Aerosphere entered the market as the only other triple inhaler, but only for COPD
• 2024–2026: Rising prescription volumes, combined with ongoing supply chain pressures and no generic entry, have led to intermittent localized stockouts

Prescribing Implications

The intermittent unavailability of Trelegy creates several challenges for prescribers:

Treatment Continuity

Patients who cannot fill their Trelegy prescription may go days or weeks without maintenance therapy. This increases exacerbation risk — particularly dangerous for patients with severe COPD (GOLD stage III–IV) or poorly controlled asthma. Studies show that even short gaps in ICS-containing regimens can lead to clinically significant declines in lung function and increased emergency utilization.

Patient Confusion and Non-Adherence

When patients are told their medication is unavailable, many are unsure what to do next. Some will ration their remaining doses, skip therapy entirely, or turn to rescue inhalers as a substitute — all suboptimal outcomes. Proactive communication from the prescriber's office can prevent these scenarios.

Prior Authorization Burden

Many payers require prior authorization for Trelegy, and some mandate step therapy through dual-combination inhalers before approving triple therapy. If you're switching a patient to an alternative due to access issues, the new medication may require its own prior authorization — adding further delay.

Current Availability Picture

As of early 2026:

• Trelegy Ellipta is not listed on the FDA Drug Shortage Database
• GSK has not issued formal supply disruption notices
• Patient-reported and pharmacy-reported availability is inconsistent, with regional and distributor-level variability
• Major chain pharmacies appear more affected than independent and specialty pharmacies
• No generic version exists; GSK patent protection extends through the late 2020s

Cost and Access Barriers

Even when Trelegy is physically available, cost remains a significant barrier:

• Cash price: $580–$700 per 30-day inhaler
• Commercial insurance: Tier 3 or Tier 4 placement; copays typically $30–$75/month
• Medicare Part D: Variable; patients in the coverage gap may face substantial out-of-pocket costs
• GSK Savings Card: Reduces copays to as little as $0/month for commercially insured patients (not valid for government insurance)
• GSK Patient Assistance (GSK For You): Free drug for qualifying uninsured/underinsured patients

For a comprehensive review of savings options, direct your patients to our guide on saving money on Trelegy.

Tools and Resources for Providers

Medfinder for Providers

Medfinder offers a provider-facing tool that helps clinicians and their staff check real-time pharmacy availability of Trelegy and other medications. Rather than having patients call multiple pharmacies, your office can identify in-stock locations and direct prescriptions accordingly.

Therapeutic Alternatives

When Trelegy is unavailable, consider these clinically appropriate alternatives:

1. Breztri Aerosphere (Budesonide/Glycopyrrolate/Formoterol) — the only other single-inhaler triple therapy; FDA-approved for COPD only; twice-daily dosing
2. Breo Ellipta + Incruse Ellipta — same three active ingredients as Trelegy delivered via two Ellipta devices; once-daily dosing for both
3. Symbicort + Spiriva — ICS/LABA MDI plus LAMA HandiHaler or Respimat; generic Symbicort available at significantly lower cost
4. Step-down to dual therapy — for patients with milder disease, Breo Ellipta (ICS/LABA) or Anoro Ellipta (LAMA/LABA) alone may be sufficient

Electronic Prescribing Tips

• When prescribing Trelegy, include a note allowing pharmacist substitution to Breztri Aerosphere if Trelegy is unavailable (where state law permits)
• Send prescriptions to pharmacies confirmed to have stock — use Medfinder to verify before transmitting
• Proactively start prior authorization when switching to an alternative

Looking Ahead

Several developments may improve access in the coming years:

• Potential generic entry in the late 2020s as GSK patents expire could increase supply and reduce costs
• Biosimilar and generic inhaler pathways are being explored by the FDA, though complex device-drug combinations present regulatory challenges
• New triple-therapy competitors may enter the market, providing additional supply sources and formulary alternatives

In the near term, proactive prescribing practices and use of availability tools remain the most effective strategies.

Final Thoughts

Trelegy Ellipta access issues in 2026 are real, even absent a formal shortage declaration. As a prescriber, your proactive involvement — from checking availability before prescribing to guiding patients through alternatives and assistance programs — can make the difference between a patient staying on therapy or going without.

Use Medfinder for Providers to streamline your workflow, and review our provider guide to helping patients find Trelegy for a step-by-step approach. For patient-facing resources, share our Trelegy shortage update for patients.